Get the composition of our in-house portfolios

All portfolios and performance
Portfolio Ref: EQ3525LS3W
Performance in the last:
Follow this Portfolio
1D -2.4 %
1W 1.0 %
2W 4.1 %
1M 6.2 %
3M 15.8 %
6M 19.9 %
9M 25.2 %
1Y -22.5 %
Alpha
-33.8%
Beta
0.54
sharpe-R
-0.46
Benchmark
SP500 (SPDR S&P 500 ETF Trust)
sharpe-R Benchmark
1.69
The portfolio metrics Alpha, Beta and Sharpe Ratio are computed using a risk free rate of 0%.
Other Information
Calculation Frequency Daily
Latest Valuation Time 2025-02-04 07:50:35
Launch Date 2023-01-01 00:00:00
First Valuation Date 2021-01-01 00:00:00
Max. DrawDown -50.18%
Max. DrawDown Benchmark -8.41%

This Long-Short strategy aims to find promising assets to invest in for a maximum holding period of 3 Weeks in the Equity asset class. This portfolio focuses only on companies in the Health Care sector. The maximum number of assets that can be allocated in this strategy is 25.

The assets selection in this portfolio is based on: Macro-Pattern Mix St..
Please note that all model portfolios assume that the entry price for each trade is the previous close price.

For Long-Short model portfolios, the short-selling costs (asset borrowing costs) are not taken into account. This assumption is likely unrealistic, and it is important to understand the short-selling process before employing this type of strategy.

Portfolio Performance against the market Benchmark

Try Our Peformance Checker Tool

Risk Level
3
Difficulty Level
4

Do you want to invest in this strategy ?

Follow the portfolio and you will get notified for every change in the composition of the portfolio

Current Portfolio Composition

Asset Asset Class Action Weight PnL
ACRS Aclaris Therapeutics, Inc. Equity Buy 7.43% -4%
NUTX Nutex Health Inc. Equity Buy 8.31% 53.16%
MD Pediatrix Medical Group, Inc. Equity Buy 7.38% -0.57%
MDXG MiMedx Group, Inc. Equity Buy 7.18% -3.17%
AXSM Axsome Therapeutics, Inc. Equity Buy 8.49% 14.59%
CERS Cerus Corporation Equity Buy 6.09% -2.7%
ATXS Astria Therapeutics, Inc. Equity Buy 7.08% -4.62%
DNLI Denali Therapeutics Inc. Equity Buy 7.38% 1.58%
NVRO Nevro Corp. Equity Buy 6.97% 17.45%
LGND Ligand Pharmaceuticals Incorporated Equity Buy 6.73% 4.06%
ORGO Organogenesis Holdings Inc. Equity Buy 7.56% 2.4%
AGEN Agenus Inc. Equity Buy 7.1% -8.36%
BLFS BioLife Solutions, Inc. Equity Buy 10.01% -5.94%
RGNX REGENXBIO Inc. Equity Buy 8.71% -3.1%
GERN Geron Corporation Equity Sell -3.66% 3.06%
MDRX Allscripts Healthcare Solutions, Inc. Equity Sell -2.75% 44.44%
FGEN FibroGen, Inc. Equity Sell -4.14% 5.56%
HROW Harrow Health, Inc. Equity Sell -4.65% 7.62%
UTMD Utah Medical Products, Inc. Equity Sell -3.24% 2.27%
AADI Aadi Bioscience, Inc. Equity Sell -3.14% 5.19%
CARA Cara Therapeutics, Inc. Equity Sell -4.89% 1.24%
ANGO AngioDynamics, Inc. Equity Sell -3.54% 0%
The percentage of cash held in the portfolio is: 23.59%
** The description of each asset is available Here

The latest 5 Compositions change

2025-02-04 00:00:00 : Portfolio change date
Asset Action Weight PnL
ACRS Aclaris Therapeutics, Inc. Buy 7.43% -4%
NUTX Nutex Health Inc. Buy 8.31% 53.16%
MD Pediatrix Medical Group, Inc. Buy 7.38% -0.57%
MDXG MiMedx Group, Inc. Buy 7.18% -3.17%
AXSM Axsome Therapeutics, Inc. Buy 8.49% 14.59%
CERS Cerus Corporation Buy 6.09% -2.7%
ATXS Astria Therapeutics, Inc. Buy 7.08% -4.62%
DNLI Denali Therapeutics Inc. Buy 7.38% 1.58%
NVRO Nevro Corp. Buy 6.97% 17.45%
LGND Ligand Pharmaceuticals Incorporated Buy 6.73% 4.06%
ORGO Organogenesis Holdings Inc. Buy 7.56% 2.4%
AGEN Agenus Inc. Buy 7.1% -8.36%
BLFS BioLife Solutions, Inc. Buy 10.01% -5.94%
RGNX REGENXBIO Inc. Buy 8.71% -3.1%
GERN Geron Corporation Sell -3.66% 3.06%
MDRX Allscripts Healthcare Solutions, Inc. Sell -2.75% 44.44%
FGEN FibroGen, Inc. Sell -4.14% 5.56%
HROW Harrow Health, Inc. Sell -4.65% 7.62%
UTMD Utah Medical Products, Inc. Sell -3.24% 2.27%
AADI Aadi Bioscience, Inc. Sell -3.14% 5.19%
CARA Cara Therapeutics, Inc. Sell -4.89% 1.24%
ANGO AngioDynamics, Inc. Sell -3.54% 0%
The percentage of cash held in the portfolio is: 23.59%
New Assets Added
  • ANGO
Assets Removed
Asset Action Perf %
AVXL Buy All 18.1%
INSM Sell All 12.98%
AXGN Sell All -1.81%
SIGA Sell All -9.55%
Assets Rebalanced
None
2025-02-03 00:00:00 : Portfolio change date
Asset Action Weight PnL
INSM Insmed Incorporated Buy 6.88% 11.1%
AXGN AxoGen, Inc. Buy 6.72% -0.22%
ACRS Aclaris Therapeutics, Inc. Buy 7.5% -0.8%
NUTX Nutex Health Inc. Buy 7.89% 48.84%
MD Pediatrix Medical Group, Inc. Buy 7.23% -0.14%
MDXG MiMedx Group, Inc. Buy 7.14% -1.36%
AXSM Axsome Therapeutics, Inc. Buy 8.21% 13.56%
CERS Cerus Corporation Buy 6.17% 1.08%
ATXS Astria Therapeutics, Inc. Buy 7.31% 0.9%
DNLI Denali Therapeutics Inc. Buy 7.69% 8.37%
NVRO Nevro Corp. Buy 6.92% 19.58%
LGND Ligand Pharmaceuticals Incorporated Buy 6.68% 5.69%
ORGO Organogenesis Holdings Inc. Buy 7.97% 10.51%
AGEN Agenus Inc. Buy 7.5% -0.78%
SIGA SIGA Technologies, Inc. Buy 7.39% -6.42%
BLFS BioLife Solutions, Inc. Buy 10.03% -3.5%
RGNX REGENXBIO Inc. Buy 8.77% 0%
AVXL Anavex Life Sciences Corp. Sell -3.4% 12.13%
GERN Geron Corporation Sell -3.59% 2.38%
MDRX Allscripts Healthcare Solutions, Inc. Sell -2.93% 39.33%
FGEN FibroGen, Inc. Sell -4.11% 3.97%
HROW Harrow Health, Inc. Sell -4.68% 4.86%
UTMD Utah Medical Products, Inc. Sell -3.23% 0.13%
AADI Aadi Bioscience, Inc. Sell -3.22% 0.35%
CARA Cara Therapeutics, Inc. Sell -4.83% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • CARA
  • RGNX
Assets Removed
Asset Action Perf %
VKTX Buy All 16.69%
TGTX Sell All -0.69%
Assets Rebalanced
None
2025-01-30 00:00:00 : Portfolio change date
Asset Action Weight PnL
INSM Insmed Incorporated Buy 7.08% 13.16%
AXGN AxoGen, Inc. Buy 6.82% 0.33%
ACRS Aclaris Therapeutics, Inc. Buy 7.21% -5.6%
NUTX Nutex Health Inc. Buy 7.49% 39.94%
MD Pediatrix Medical Group, Inc. Buy 7.42% 1.36%
MDXG MiMedx Group, Inc. Buy 7.51% 2.61%
AXSM Axsome Therapeutics, Inc. Buy 8.2% 12.15%
CERS Cerus Corporation Buy 6.47% 4.86%
ATXS Astria Therapeutics, Inc. Buy 7.01% -4.24%
DNLI Denali Therapeutics Inc. Buy 7.8% 8.88%
NVRO Nevro Corp. Buy 6.98% 19.34%
LGND Ligand Pharmaceuticals Incorporated Buy 6.88% 7.83%
ORGO Organogenesis Holdings Inc. Buy 8.32% 14.11%
AGEN Agenus Inc. Buy 7.2% -5.74%
SIGA SIGA Technologies, Inc. Buy 7.82% -2.03%
TGTX TG Therapeutics, Inc. Buy 7.3% 4.54%
BLFS BioLife Solutions, Inc. Buy 10.5% 0%
VKTX Viking Therapeutics, Inc. Sell -2.99% 14.96%
AVXL Anavex Life Sciences Corp. Sell -3.6% 8.06%
GERN Geron Corporation Sell -3.66% 1.7%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.13% 15.44%
FGEN FibroGen, Inc. Sell -4.12% 4.76%
HROW Harrow Health, Inc. Sell -4.98% -0.19%
UTMD Utah Medical Products, Inc. Sell -3.27% 0%
AADI Aadi Bioscience, Inc. Sell -3.27% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • UTMD
  • AADI
  • BLFS
Assets Removed
Asset Action Perf %
ORMP Buy All 5.46%
AORT Sell All 3.27%
Assets Rebalanced
None
2025-01-29 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 7.29% 2.68%
INSM Insmed Incorporated Buy 7.2% 13.83%
AXGN AxoGen, Inc. Buy 6.94% 0.88%
ACRS Aclaris Therapeutics, Inc. Buy 7.38% -4.4%
NUTX Nutex Health Inc. Buy 7.24% 33.72%
MD Pediatrix Medical Group, Inc. Buy 7.64% 3.29%
MDXG MiMedx Group, Inc. Buy 7.6% 2.72%
AXSM Axsome Therapeutics, Inc. Buy 8.08% 9.29%
CERS Cerus Corporation Buy 7.15% 14.59%
ATXS Astria Therapeutics, Inc. Buy 7.11% -3.85%
DNLI Denali Therapeutics Inc. Buy 7.92% 9.3%
NVRO Nevro Corp. Buy 6.96% 17.69%
LGND Ligand Pharmaceuticals Incorporated Buy 6.91% 7.1%
ORGO Organogenesis Holdings Inc. Buy 7.88% 6.91%
AGEN Agenus Inc. Buy 7.18% -7.05%
SIGA SIGA Technologies, Inc. Buy 7.83% -2.97%
TGTX TG Therapeutics, Inc. Buy 7.39% 4.79%
ORMP Oramed Pharmaceuticals Inc. Sell -3.3% 5.46%
VKTX Viking Therapeutics, Inc. Sell -3.1% 12.69%
AVXL Anavex Life Sciences Corp. Sell -3.71% 6.07%
GERN Geron Corporation Sell -3.84% -2.04%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.39% 11.11%
FGEN FibroGen, Inc. Sell -4.25% 2.78%
HROW Harrow Health, Inc. Sell -5.09% -1.27%
The percentage of cash held in the portfolio is: 2%
New Assets Added
None
Assets Removed
Asset Action Perf %
FATE Buy All 25.71%
Assets Rebalanced
Asset Action Weight
AXGN Sell -0.84%
TGTX Sell -5.51%
AXSM Buy 0.24%
DNLI Buy 0.36%
SIGA Buy 0.47%
ORGO Buy 1.03%
2025-01-28 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 7.22% 1.36%
AXGN AxoGen, Inc. Buy 7.6% -1.75%
INSM Insmed Incorporated Buy 7.14% 12.62%
ACRS Aclaris Therapeutics, Inc. Buy 7.59% -2%
NUTX Nutex Health Inc. Buy 6.87% 26.44%
MD Pediatrix Medical Group, Inc. Buy 7.78% 4.86%
MDXG MiMedx Group, Inc. Buy 7.33% -1.25%
ATXS Astria Therapeutics, Inc. Buy 7.19% -3.21%
AXSM Axsome Therapeutics, Inc. Buy 7.19% 9.54%
LGND Ligand Pharmaceuticals Incorporated Buy 6.88% 6.35%
DNLI Denali Therapeutics Inc. Buy 6.97% 7.86%
CERS Cerus Corporation Buy 7.27% 16.22%
NVRO Nevro Corp. Buy 7.01% 18.16%
ORGO Organogenesis Holdings Inc. Buy 7.21% 12.31%
AGEN Agenus Inc. Buy 7.28% -6.01%
SIGA SIGA Technologies, Inc. Buy 7.1% -0.78%
TGTX TG Therapeutics, Inc. Buy 12.35% 0%
FATE Fate Therapeutics, Inc. Sell -2.75% 21.71%
ORMP Oramed Pharmaceuticals Inc. Sell -3.3% 5.88%
VKTX Viking Therapeutics, Inc. Sell -3.03% 14.88%
AVXL Anavex Life Sciences Corp. Sell -3.69% 6.92%
GERN Geron Corporation Sell -3.8% -0.68%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.14% 16.33%
FGEN FibroGen, Inc. Sell -4.24% 3.17%
HROW Harrow Health, Inc. Sell -5.04% 0%
The percentage of cash held in the portfolio is: 2%
New Assets Added
  • HROW
  • TGTX
Assets Removed
Asset Action Perf %
ESPR Sell All -14.96%
Assets Rebalanced
None
2025-01-27 00:00:00 : Portfolio change date
Asset Action Weight PnL
AORT Artivion, Inc. Buy 7.29% 1.42%
ESPR Esperion Therapeutics, Inc. Buy 7.81% -10.26%
AXGN AxoGen, Inc. Buy 7.76% -0.6%
INSM Insmed Incorporated Buy 7.29% 13.85%
ACRS Aclaris Therapeutics, Inc. Buy 7.85% 0.4%
NUTX Nutex Health Inc. Buy 7.29% 32.94%
MD Pediatrix Medical Group, Inc. Buy 7.66% 2.29%
MDXG MiMedx Group, Inc. Buy 7.47% -0.34%
ATXS Astria Therapeutics, Inc. Buy 7.13% -4.88%
AXSM Axsome Therapeutics, Inc. Buy 7.29% 9.98%
LGND Ligand Pharmaceuticals Incorporated Buy 6.81% 4.31%
DNLI Denali Therapeutics Inc. Buy 6.74% 3.35%
CERS Cerus Corporation Buy 6.73% 6.49%
NVRO Nevro Corp. Buy 7.29% 21.7%
ORGO Organogenesis Holdings Inc. Buy 6.93% 6.91%
AGEN Agenus Inc. Buy 7.29% -6.79%
SIGA SIGA Technologies, Inc. Buy 7.29% 0.94%
FATE Fate Therapeutics, Inc. Sell -2.69% 24%
ORMP Oramed Pharmaceuticals Inc. Sell -3.37% 4.62%
VKTX Viking Therapeutics, Inc. Sell -3.16% 12.24%
AVXL Anavex Life Sciences Corp. Sell -3.98% 0.57%
GERN Geron Corporation Sell -3.9% -2.38%
MDRX Allscripts Healthcare Solutions, Inc. Sell -4.33% 13.33%
FGEN FibroGen, Inc. Sell -4.47% -0.99%
The percentage of cash held in the portfolio is: 2%
New Assets Added
None
Assets Removed
Asset Action Perf %
TGTX Buy All -11.64%
Assets Rebalanced
Asset Action Weight
DNLI Sell -1.01%
LGND Sell -1%
CERS Sell -1.25%
AXSM Sell -0.95%
INSM Sell -1.6%
NVRO Sell -1.83%
NUTX Sell -3.11%
ESPR Buy 0.93%
AORT Buy 1.02%
AGEN Buy 1.34%
SIGA Buy 2.95%

Load more previous compositions

Compositions In The Last 2W Compositions In The Last 1M Compositions In The Last 3M Compositions In The Last 6M

Market Overview

Disclaimer Quantam Research does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, assets forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.
Cookies Settings